Clinical Trials

Study Title:
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (M18-868)

For more information about the trial above please contact the study team: Medical University of South Carolina Principal Investigator, Mariam Alexander, at alexanma@musc.edu. Study Coordinator, Jessica Shealor, at shealorj@musc.edu. Trial opened at the following institutions: Medical University of South Carolina